Wall Street analyst estimates for Artiva Biotherapeutics, Inc. (ARTV): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-11 | $-0.54 | ||
| 2026-08-06 | $-0.63 | $-0.63 | -0.8% |
| 2026-05-08 | $-0.95 | $-0.88 | -8.0% |
| 2026-03-10 | $-0.84 | $-0.87 | +3.4% |
| 2025-11-12 | $-0.88 | $-0.92 | +4.3% |
| 2025-08-06 | $-0.87 | $-0.84 | -3.6% |
| 2025-05-08 | $-0.83 | $-0.68 | -22.1% |
| 2025-03-25 | $-0.66 | $-0.71 | +7.0% |
Valuation Ratios
| Price / Book | 0.98 |
| EV / EBITDA | -2.38 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0 | $2.0M | $4.9M | $33.5M | $251000 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | $2.6M |
| Gross Profit | 0 | $2.0M | $4.9M | $33.5M | $251000 | -$2.6M |
| Research & Development | $13.8M | $42.4M | $44.0M | $50.3M | $50.3M | $69.5M |
| Selling, General & Admin | $4.4M | $12.9M | $20.8M | $13.9M | $17.2M | $20.3M |
| Operating Expenses | $18.3M | $55.3M | $64.8M | $64.2M | $67.5M | $88.0M |
| Operating Income | -$18.3M | -$53.3M | -$59.8M | -$30.7M | -$67.3M | -$90.6M |
| EBITDA | -$17.5M | -$71.6M | -$57.2M | -$25.4M | -$56.1M | -$81.3M |
| Interest Expense | $199000 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$18.0M | -$71.8M | -$58.3M | -$27.6M | -$58.5M | -$83.9M |
| Income Tax | 0 | 0 | $53000 | $72000 | 0 | 0 |
| Net Income | -$18.0M | -$71.8M | -$58.4M | -$27.7M | -$58.5M | -$83.9M |
| EPS | $-1.02 | $-4.08 | $-3.32 | $-1.19 | $-5.20 | $-3.43 |
| EPS (Diluted) | $-1.02 | $-4.08 | $-3.32 | $-1.19 | $-5.20 | $-3.43 |
| Shares Outstanding (Diluted) | $17.6M | $17.6M | $17.6M | $23.3M | $24.4M | $24.4M |
Price
| Price | $8.60 |
| Market Cap | $420M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ADVM · ALXO · CNTB · DTIL · GUTS · IFRX · MGX
Explore sector: Healthcare · Biotechnology
More sections of ARTV: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks